July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Presence and progression of atrophic areas in pathological myopia
Charlotte Anne Melzer; Focke Ziemssen; Nicole Eter; Christian Karl Brinkmann; Hansjürgen Agostini; Gisela Haeusser-Fruh; Uwe Rose; Marc Schargus; Katrin Lorenz; Frank G Holz; Steffen Schmitz-Valckenberg
Author Affiliations & Notes
  • Charlotte Anne Melzer
    Department of Ophthalmology, University of Bonn, Bonn, Germany
  • Focke Ziemssen
    Department of Ophthalmology, Eberhard Karls University Tuebingen, Germany
  • Nicole Eter
    Department of Ophthalmology, University of Muenster, Germany
  • Christian Karl Brinkmann
    Department of Ophthalmology, University of Bonn, Bonn, Germany
  • Hansjürgen Agostini
    Eye Center, University of Freiburg, Germany
  • Gisela Haeusser-Fruh
    Novartis Germany, Germany
  • Uwe Rose
    Novartis Germany, Germany
  • Marc Schargus
    Asklepios Klinik North-Heidberg Hamburg, Germany
  • Katrin Lorenz
    Department of Ophthalmology, University of Mainz, Germany
  • Frank G Holz
    Department of Ophthalmology, University of Bonn, Bonn, Germany
  • Steffen Schmitz-Valckenberg
    Department of Ophthalmology, University of Bonn, Bonn, Germany
  • Footnotes
    Commercial Relationships   Charlotte Melzer, Alcon/Novartis (F), Alcon/Novartis (R), Carl Zeiss MediTec (F), CenterVue (F), Heidelberg Engineering (F), Optos (F); Focke Ziemssen, Alimera (C), Allergan (C), Allergan (R), Bayer Healthcare (C), Biogen (R), Boehringer-Ingelheim (C), Clearside (R), Genetech/Roche (C), Genetech/Roche (R), MSD (C), Novartis (C), Novartis (R), Novo/Nordisk (C); Nicole Eter, Alimera (R), Allergan (C), Allergan (R), Bayer (C), Bayer (F), Bayer (R), Heidelberg Engineering (R), Novartis (C), Novartis (F), Novartis (R), Roche (C); Christian Brinkmann, Allergan/Novartis (C), Allergan/Novartis (F), Allergan/Novartis (R), Carl Zeiss MediTec (F), Carl Zeiss MediTec (C), Carl Zeiss MediTec (R), Heidelberg Engineering (F), Heidelberg Engineering (R), Newtricious (F), Newtricious (R); Hansjürgen Agostini, Allergan (F), Allergan (C), Bayer (R), Carl Zeiss MediTec (C), Carl Zeiss MediTec (F), Carl Zeiss MediTec (R), Novartis (F), Novartis (C), Novartis (R), Roche (C), Roche (R); Gisela Haeusser-Fruh, Novartis Germany (F), Novartis Germany (E); Uwe Rose, Novartis Germany (F), Novartis Germany (E); Marc Schargus, Allcon/Novartis (C), Allcon/Novartis (F); Katrin Lorenz, Aerie Pharmaceuticals (F), Alcon (F), Alimera (F), Allergan (F), Bayer (F), Bioeq (F), Boehringer Ingelheim (F), Boehringer Ingelheim (C), Chroma Pharma (C), Chroma Pharma (F), Chroma Pharma (R), Isarna Therapeutics (C), Isarna Therapeutics (F), Novartis (F), Novartis (C), Pfizer (F), Quark Pharmaceuticals (F), Regeneron (F), Roche (C), Roche (F), Santen (F), Shire (F), Synteract HCR (C), Thea (F), Thromogenics (F); Frank Holz, Acucela (C), Acucela (F), Acucela (R), Allergan/Novarits (C), Allergan/Novartis (F), Allergan/Novartis (R), Apelis (C), Apelis (R), Bayer (C), Bayer (F), Bayer (R), Bioeq/Formycon (F), Bioeq/Formycon (C), Boehringer-Ingelheim (C), Carl Zeiss MediTec (F), CenterVue (F), Elley (R), Heidelberg Engineering (F), Heidelberg Enigineering (C), LinBioscience (C), NightStarX (F), Optos (F), Roche/Genentech (C), Roche/Genentech (F), Roche/Genentech (R); Steffen Schmitz-Valckenberg, Acucela (F), Alcon/Novartis (C), Alcon/Novartis (F), Alcon/Novartis (R), Bayer (F), Bayer (R), Bioeq/Formycon (C), Bioeq/Formycon (F), Carl Zeiss MediTec (F), Carl Zeiss MediTec (R), CenterVue (F), Galimedix (C), Genentech/Roche (F), Genentech/Roche (R), Heidelberg Engineering (F), Katairo (F), Optos (F)
  • Footnotes
    Support  Novartis
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4352. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Presence and progression of atrophic areas in pathological myopia
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Charlotte Anne Melzer, Focke Ziemssen, Nicole Eter, Christian Karl Brinkmann, Hansjürgen Agostini, Gisela Haeusser-Fruh, Uwe Rose, Marc Schargus, Katrin Lorenz, Frank G Holz, Steffen Schmitz-Valckenberg; Presence and progression of atrophic areas in pathological myopia. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4352.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose : The multicenter, longitudinal HELP observational study prospectively investigates the natural course of pathological myopia in Caucasians. The aim of this analysis was to evaluate the development and progression of atrophy areas.

Methods : One hundred and fifty subjects (age: 57.2 (± 12.7) years) were recruited in 25 centers across Germany between 2014 and 2016. Main inclusion criteria included axial length> 26 mm, best corrected visual acuity (BCVA) ≥ 0.05 and the presence of at least one of five pre-defined morphological risk factors in the study eye approved by the independent central reading center (CRC). At baseline and annual visits, the presence and localisation of atrophy in study and non-study eye were determined by multimodal imaging including color fundus photography (three-field imaging), fundus autofluorescence (two-field imaging), and spectral domain optical coherence tomography (central 30 ° field) by the CRC. If possible, area size was quantified using RegionFinder software and the enlargement rate of atrophy over the time was determinted for up to three atrophy areas per eye, provided individual spots were completely covered within the field of view. (German Clinical Trial Register DRKS00007761).

Results : At least one atrophic area was present in 82 eyes of 61 (40.6%) patients at baseline, of which 26 eyes presenting more than three lesions. In 58 eyes, atrophy areas were completely detected within two-field fundus autofluorescence imaging, while in the remaining 24 eyes the atrophy areas partially exceeded the edge of the image field. Mean size of single atrophic spots was 1.29 mm2 (range, 0.01-11.07 mm2) and mean total lesion size per eye was 1.90 (0.05-31.03 mm2), respectively. On average, atrophy areas increased by 0.24 mm2/year (0-1.93 mm2) in the first, by 0.2 mm2/year (0-1.33 mm2) in the second and by 0.21 mm2/year (0-1.19 mm2) in the third year.

Conclusions : The progression of atrophic areas in pathological myopia can be quantified by multimodal imaging. The annual enlargement rate is highly variable and markedly lower compared to the progression of geographic atrophy associated with age-related macular degeneration.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Attribution-NonCommercial-NoDerivatives
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept